#Paris #France #Astraveus #CAR-T Cells #Microfluidic Technology

Astraveus Breakthrough in CAR-T Cell Production

In a significant advancement in the field of cell therapy, Astraveus SAS, a Paris-based life science firm, has successfully launched the first-ever automated, end-to-end production of CAR-T cells utilizing its innovative microfluidic technology. This milestone is not only a testament to the technological ingenuity behind the Lakhesys Benchtop Cell Factory™, but it also signals a new era for cell therapy, offering increased throughput and decreased manufacturing costs.

The Lakhesys Benchtop Cell Factory™ operates as a fully integrated system that brings together cell therapy production processes and onboard analytics into a single, efficient platform. By employing cutting-edge microfluidic technology, the system promises to optimize cell quality while ensuring effective processing. The scalable parallelization from pre-clinical to commercial manufacturing phases is designed to minimize costs significantly and reduce laboratory space requirements, ultimately enhancing the accessibility of life-saving therapies.

According to Jérémie Laurent, PhD and CEO of Astraveus, this innovation marks an exciting juncture for the company. “We are incredibly excited to see our team's efforts come to fruition as we prepare for the launch of the Lakhesys Benchtop Cell Factory. For the first time, CAR-T cells have been successfully produced using a fully automated, end-to-end microfluidic system, delivering the proof of concept for our purpose-built benchtop cell factory.”

The production time for these CAR-T cells is notably reduced to just 26 hours, showcasing the efficiency of their bead-free microfluidic selection technology. This swift turnaround not only suggests operational enhancements but also indicates the potential for cost-effective solutions compared to existing technologies in the market.

Prof. Jérôme Larghero, a distinguished member of Astraveus' Scientific Advisory Board, proclaimed that this technological advancement paves the way for more scalable, affordable, and decentralized production models for cell therapies, establishing a new standard of care in the medical field. He emphasized the tremendous implications this technology holds for patients, particularly those in need of innovative treatment solutions.

The Vision of Astraveus

Founded in 2016 within the renowned Saint-Louis Hospital in Paris—a leading hub for cell therapy research—Astraveus is committed to revolutionizing the landscape of cell therapy and making these exceptional treatments accessible to everyone, regardless of their circumstances. The company’s overarching goal is to elevate the standard of healthcare and facilitate a healthier tomorrow by focusing on maximizing quality while drastically reducing production costs.

As Astraveus prepares for the commercial debut of the Lakhesys Benchtop Cell Factory™, it aims to remain at the forefront of bioprocessing innovation, addressing the demands of cellular manufacturing with a resolute commitment to excellence.

For more information on this groundbreaking technology, visit Astraveus' website.